Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Postmenopausal, ambulatory women between 50 and 70 years old who are generally in good health.~* Must have low bone mineral density and meet specific eligibility criteria.~Key Exclusion Criteria:~-Subjects must not currently be receiving any medication that affects bone metabolism or have an underlying condition that affects their ability to take alendronate or receive denosumab.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 3 (Type: PLACEBO_COMPARATOR): Placebo for denosumab and placebo for alendronate
- 1 (Type: EXPERIMENTAL): denosumab and placebo for alendronate
- 2 (Type: ACTIVE_COMPARATOR): Placebo for denosumab and alendronate

Based on this trial design, predict the completion outcome and termination type (if applicable).